Jyong Biotech Ltd.
MENS
$55.24
$1.182.18%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.39% | -41.39% | -20.84% | -20.84% | 14.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.54% | -34.54% | -14.25% | -14.25% | 4.46% |
| Operating Income | 34.54% | 34.54% | 14.25% | 14.25% | -4.46% |
| Income Before Tax | 36.31% | 36.31% | 23.88% | 23.88% | 43.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.31% | 36.31% | 23.88% | 23.88% | 43.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.31% | 36.31% | 23.88% | 23.88% | 43.33% |
| EBIT | 34.54% | 34.54% | 14.25% | 14.25% | -4.46% |
| EBITDA | 35.61% | 35.61% | 14.85% | 14.85% | -4.77% |
| EPS Basic | 36.56% | 36.56% | 23.77% | 23.77% | 43.29% |
| Normalized Basic EPS | 36.21% | 36.21% | 23.68% | 23.68% | 43.41% |
| EPS Diluted | 36.56% | 36.56% | 23.77% | 23.77% | 43.29% |
| Normalized Diluted EPS | 36.21% | 36.21% | 23.68% | 23.68% | 43.41% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |